PMID- 26025562
OWN - NLM
STAT- MEDLINE
DCOM- 20160617
LR  - 20191210
IS  - 1879-1379 (Electronic)
IS  - 0022-3956 (Linking)
VI  - 68
DP  - 2015 Sep
TI  - Changes in cognitive symptoms after a buspirone-melatonin combination treatment 
      for Major Depressive Disorder.
PG  - 392-6
LID - S0022-3956(15)00127-2 [pii]
LID - 10.1016/j.jpsychires.2015.04.024 [doi]
AB  - Cognitive deficits are often associated with acute depressive episodes and 
      contribute to the functional impairment seen in patients with Major Depressive 
      Disorder (MDD). Many patients sustain residual cognitive deficits after treatment 
      that may be independent of the core MDD disorder. We tracked changes in cognitive 
      deficits relative to antidepressant treatment response using the patient 
      self-rated Massachusetts General Hospital Cognitive and Physical Functioning 
      Questionnaire (MGH-CPFQ) during a 6-week, double-blind trial of a combination 
      antidepressant treatment (buspirone 15 mg with melatonin-SR 3 mg) versus 
      buspirone (15 mg) monotherapy versus placebo in MDD patients with acute 
      depressive episodes. The CPFQ includes distinct cognitive and physical 
      functioning dimension subscales. Treatment response was determined using the 
      Inventory of Depressive Symptomatology (IDSc30). Treatment responders improved 
      significantly more on the total CPFQ than non-responders (p < 0.0001) regardless 
      of treatment assignment. The cognitive dimension of the CPFQ score favored the 
      combination treatment over the other two groups (ANCOVA: p = 0.050). Among the 
      treatment non-responders, the effect size for the CPFQ cognitive dimension was 
      0.603 favoring the combination treatment over the over two groups and 0.113 for 
      the CPFQ physical dimension. These preliminary findings suggest that a 
      combination of buspirone with melatonin may benefit cognitive function distinct 
      from mood symptoms and that some aspects of cognition may be specific targets for 
      treatment within a population of patients with MDD.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Targum, Steven D
AU  - Targum SD
AD  - Clintara LLC, Boston, MA, USA. Electronic address: sdtargum@yahoo.com.
FAU - Wedel, Pamela C
AU  - Wedel PC
AD  - BrainCells Inc., San Diego, CA, USA. Electronic address: scoutwedel@yahoo.com.
FAU - Fava, Maurizio
AU  - Fava M
AD  - Massachusetts General Hospital, Boston, MA, USA. Electronic address: 
      mfava@mgh.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150509
PL  - England
TA  - J Psychiatr Res
JT  - Journal of psychiatric research
JID - 0376331
RN  - 0 (Antioxidants)
RN  - 0 (Serotonin Receptor Agonists)
RN  - JL5DK93RCL (Melatonin)
RN  - TK65WKS8HL (Buspirone)
SB  - IM
MH  - Acute Disease
MH  - Antioxidants/administration & dosage/*pharmacology
MH  - Buspirone/administration & dosage/*pharmacology
MH  - Cognition Disorders/*drug therapy/etiology
MH  - Depressive Disorder, Major/complications/*drug therapy
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Melatonin/administration & dosage/*pharmacology
MH  - *Outcome Assessment, Health Care
MH  - Serotonin Receptor Agonists/administration & dosage/*pharmacology
OTO - NOTNLM
OT  - Anti-depressant treatment
OT  - CPFQ
OT  - Cognition
OT  - Depression
EDAT- 2015/05/31 06:00
MHDA- 2016/06/18 06:00
CRDT- 2015/05/31 06:00
PHST- 2014/11/10 00:00 [received]
PHST- 2015/04/25 00:00 [revised]
PHST- 2015/04/30 00:00 [accepted]
PHST- 2015/05/31 06:00 [entrez]
PHST- 2015/05/31 06:00 [pubmed]
PHST- 2016/06/18 06:00 [medline]
AID - S0022-3956(15)00127-2 [pii]
AID - 10.1016/j.jpsychires.2015.04.024 [doi]
PST - ppublish
SO  - J Psychiatr Res. 2015 Sep;68:392-6. doi: 10.1016/j.jpsychires.2015.04.024. Epub 
      2015 May 9.